Prostate cancer DNA vaccine - Vical

Drug Profile

Prostate cancer DNA vaccine - Vical

Latest Information Update: 08 Oct 2002

Price : $50

At a glance

  • Originator Vical
  • Class Cancer vaccines; DNA vaccines; Gene therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 08 Oct 2002 Discontinued - Preclinical for Prostate cancer in USA (unspecified route)
  • 02 May 2000 New profile
  • 02 May 2000 Preclinical development for Prostate cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top